Corvus Pharmaceuticals is advancing soquelitinib, an ITK inhibitor, for peripheral T-cell lymphoma with a Phase 3 trial expected to start soon. Soquelitinib has shown promising Phase 1 data ...
How Important Is Unrelated Donor Human Leukocyte Antigen Disparity in the Post-Transplant Cyclophosphamide Era? Clinical trials frequently include multiple end points that mature at different times.